A Top Journalist is Suing the FDA Over Its Alleged Use of a Banned and Secretive Practice to Manipulate the News
By Dave Mosher,
Business Insider
| 09. 24. 2016
The US Food and Drug Administration (FDA) may reportedly still engage in a banned practice that manipulates popular news coverage, and a few of America's top science journalists are railing against the government organization because of it.
One of them is even suing the FDA for documents related to the matter.
The commotion, raised by NYU journalism professor Charles Seife in a feature story at Scientific American, deals with the FDA's use of a worrisome media strategy called a "close-hold embargo." (Seife's NYU colleague and journalist Ivan Oransky previously detailed the matter in a series of posts at his blog Embargo Watch.)
Close-hold embargoes let a select few journalists get access to newsworthy information, yet only after they agree not contact anyone outside the organization for second opinions.
The result is that due diligence goes out the window: Without the ability to contact outside experts, a bunch of stories appear in the most popular news outlets in the world all at once — yet without any independent expert voices to backstop the new information.
And with the FDA, the...
Related Articles
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
